Empirical Treatment of Community‐Acquired Pneumonia and the Development of Fluoroquinolone‐Resistant Tuberculosis | Zendy

Richard Long | Zendy; Huey Yi Chong | Zendy; Ver Hoeppner | Zendy; Hareishun Shanmuganathan | Zendy; Kinga KowalewskaGrochowska | Zendy; Cary Shandro | Zendy; Jure Manfreda | Zendy; Ambikaipakan Senthilselvan | Zendy; Abeer Elzainy | Zendy; Thomas J. Marrie | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Empirical Treatment of Community‐Acquired Pneumonia and the Development of Fluoroquinolone‐Resistant Tuberculosis

Author(s) -

Richard Long,

Huey Yi Chong,

Ver Hoeppner,

Hareishun Shanmuganathan,

Kinga KowalewskaGrochowska,

Cary Shandro,

Jure Manfreda,

Ambikaipakan Senthilselvan,

Abeer Elzainy,

Thomas J. Marrie

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/598196

Subject(s) - medicine , tuberculosis , pneumonia , community acquired pneumonia , intensive care medicine , empirical treatment , antibiotics , microbiology and biotechnology , pathology , biology

BACKGROUND" Fluoroquinolone (FLQ) antibiotics are not uncommonly prescribed for community-acquired pneumonia that is later proven to be pulmonary tuberculosis (TB). Such FLQ monotherapy may result in FLQ-resistant pulmonary TB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research